US FDA’s Advisory Committee Recommend AstraZeneca PT027 as Rescue Treatment for Asthma
The US Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) has recommended AstraZeneca’s PT027 for the treatment of asthma in people aged 18 years and older. The Committee has voted 9 to 8 for adolescents aged 12 to 17 years, and the data do not support a favourable risk assessment for the use […]
Continue Reading